

MYRIAD GENETICS INC  
Form 8-K  
May 04, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 4, 2010**

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction

of incorporation)

**0-26642**  
(Commission File Number)

**320 Wakara Way**

**Salt Lake City, Utah 84108**

**87-0494517**  
(IRS Employer

Identification No.)

Edgar Filing: MYRIAD GENETICS INC - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION**

On May 4, 2010, Myriad Genetics, Inc. ( Myriad or the Company ) announced its financial results for the three and nine months ended March 31, 2010. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**ITEM 8.01 OTHER EVENTS**

On May 4, 2010, the Company announced that its Board of Directors authorized the repurchase of \$100 million of the Company s outstanding common stock. In connection with this stock repurchase authorization, the Company plans to repurchase \$100 million of shares of its common stock from time-to-time in open market purchases or privately negotiated purchases as determined by the Company s management. The Company expects to complete the share repurchase on or before December 31, 2010.

**ITEM 9.01 Financial Statements and Exhibits.**

(d)

<b>Exhibit Number</b>	<b>Description</b>
99.1	Earnings release dated May 4, 2010 for the three and nine months ended March 31, 2010.
99.2	Press release dated May 4, 2010 announcing Board of Directors authorization of a share repurchase program.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYRIAD GENETICS, INC.**

Date: May 4, 2010

By: /s/ Peter D. Meldrum  
Peter D. Meldrum  
President and Chief Executive Officer

Page 3

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Earnings release dated May 4, 2010 for the three and nine months ended March 31, 2010.
99.2	Press release dated May 4, 2010 announcing Board of Directors authorization of a share repurchase program.